The Rhyme: The $400B Pharma Mega-Merger & Its 1999 Echo

"History doesn't repeat… but it rhymes." — Mark Twain

AstraZeneca and Bristol Myers Squibb have held preliminary talks about a merger that would create a pharmaceutical company worth roughly $400 billion, according to the Financial Times. AstraZeneca shares dropped as much as 7% in London on Monday morning, their steepest decline since early July, while Bristol Myers jumped 6% in New York. The deal, if it closes, would be the largest pharmaceutical merger in history. It would also mean the company that rejected Pfizer's $117 billion hostile takeover attempt in 2014 is now the one reaching for its own checkbook.

AZN: -7.0%  |  BMY: +6.0%  |  Combined: ~$400B  |  S&P 500: 7,588  |  Brent: $83.51

The last time a pharma deal this big hit the tape, it started with a fight over a cholesterol pill and ended with the second most expensive corporate brawl of the twentieth century.

On the morning of November 4, 1999, Warner-Lambert CEO Lodewijk de Vink stood before a bank of cameras in Morris Plains, New Jersey, and announced a merger with American Home Products worth roughly $71 billion. The deal would create the largest pharmaceutical company in the world. The press releases were out. The conference calls were booked. By lunchtime, the whole plan was already falling apart.

Five hours later, Pfizer CEO Bill Steere walked into his own press conference in midtown Manhattan and launched an unsolicited $82.4 billion counter-bid for Warner-Lambert. Pfizer's argument was blunt: it had been co-promoting a cholesterol drug called Lipitor with Warner-Lambert since 1997, and Pfizer's sales force was writing the majority of prescriptions. Without Pfizer's army of reps visiting doctors' offices every morning, Lipitor was a good drug. With them, it was a machine. And Steere was not going to let American Home Products walk off with the machine.

Lipitor was already doing nearly $4 billion a year by then, and every analyst on Wall Street knew it was going to become the biggest-selling drug in history. It lowered LDL cholesterol more effectively than anything else on the market, and patients took it for life. Whoever controlled Warner-Lambert controlled the franchise. So began a three-month corporate brawl that involved midnight board calls, lawsuits in Delaware Chancery Court, escalating bids, and two CEOs who couldn't stand each other.

On February 7, 2000, Pfizer won. The final price was $90 billion in stock. American Home Products walked away with a $1.8 billion breakup fee — the largest consolation prize in deal history at the time — and not much else. Pfizer was now the biggest drug company on the planet, and it had the most valuable drug in the world locked inside its portfolio. What nobody discussed at the closing dinner was the clock that had already started ticking. Lipitor's U.S. patent would expire in November 2011. That gave Pfizer eleven years to find or buy the next Lipitor. They never did.

Both deals arrived at the exact moment the acquirer's growth story needed a new chapter. AstraZeneca faces biosimilar competition in oncology. Pfizer faced a pipeline that ended at Lipitor. Both reached for the checkbook instead of the lab bench.

After Pfizer closed the Warner-Lambert deal on June 19, 2000, the revenue numbers were staggering. Lipitor hit $9.2 billion in 2003. It crossed $12 billion in 2005 and peaked at $12.9 billion in 2006, the highest annual revenue any single prescription drug had ever generated. Pfizer used the cash and the confidence to acquire again. Pharmacia for $60 billion in 2003. Wyeth for $68 billion in 2009. It even tried to buy AstraZeneca itself in 2014 for $117 billion, but Soriot slammed the door.

Here is the part that matters. In November 1999, when Bill Steere launched that hostile bid, Pfizer stock was trading around $39 a share. Today, twenty-seven years later, Pfizer trades around $25. The most aggressive pharmaceutical acquirer in history, the company that bet bigger on scale than anyone else in the industry, has destroyed roughly a third of its shareholders' equity in nominal terms. Adjusted for inflation, the real damage is closer to 60%. Every mega-merger produced a sugar rush of cost savings for two or three years, and then the patent cliff arrived, and the pipeline was thinner than anyone expected, and the company needed another deal to fill the hole. It was a treadmill. And it only ran in one direction.

AstraZeneca shareholders watching these BMY rumors should look at that treadmill carefully. If AZN pays a 25% premium for Bristol Myers, it would commit roughly $165 billion to a company whose biggest recent strategic move was licensing five immunology assets to a new company backed by Bain Capital. The integration of tens of thousands of employees across two continents would consume three to four years of management time — right when AZN's own cancer drugs face growing biosimilar competition. Smart money in 1999 did one thing when these rumors started: it bought the target and waited for the premium to rise. The acquirer paid the integration tax. The target cashed the check.

The Edge: In the Pfizer playbook, the acquirer's stock went nowhere for a generation while the target's shareholders collected their premium and moved on. If the AZN-BMY pattern holds, the premium flows one direction — toward Bristol Myers.

If AZN-BMY reaches a formal offer, history says a second mega-deal follows within six months. After Pfizer won Warner-Lambert in February 2000, Glaxo Wellcome and SmithKline Beecham closed their own $75 billion merger before year's end. The 1999 pharma wave did not stop until four deals had reshuffled the entire industry.